Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

Refer a Patient to MSKCC: mskcc.org/refer

 

Cleveland Clinic's 20th Annual ASH Review
A

2019 ASH Review of Frontline CLL: Is There a Role for FCR in 2020 and for Which Pts? Does E1912 Suggest Ibrutinib Can Be Considered a Time Limited Therapy?

By Cleveland Clinic's 20th Annual ASH Review FEATURING Anthony R. Mato
By Cleveland Clinic's 20th Annual ASH Review FEATURING Anthony R. Mato
0 views
April 14, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou

Featured Video

05:59
Lilly Medical Affairs

Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and …

Feat. J. O’Shaughnessy
Leukemia
18:42
Memorial Sloan Kettering Cancer Center

Key Updates in AML, MDS, & MF From ASH

Feat. A. Goldberg
15:23
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Updates on the Role of SCT in ALL in the Era of CAR-T

Feat. J. Park
13:15
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Menin Inhibition for KMT2A-Rearranged ALL

Feat. E. Stein
30:21
International CML Foundation

ASH 2022 Highlights on CML: Clinical Overview From iCMLf

Feat. M. Mauro
04:55
ASH 2022 Conference Coverage

ASH 2022 Initial Results From SELECT-AML-1: a Phase 2 Study of Tamib…

Feat. E. Stein
04:22
EHA 2022 Conference Coverage

EHA 2022 Tamibarotene in Combination With Ven & Aza in Previousl…

Feat. E. Stein
54:58
PleXus Communications

Expert Perspectives on Treating High-Risk and R/R AML

Feat. E. Stein
04:36
ecancer

Safety & Efficacy of Asciminib for Heavily Pretreated Patients W…

Feat. M. Mauro
05:49
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on the Safety & Efficacy of Menin Inhibition in …

Feat. E. Stein
16:42
University of Miami's 2nd Biennial Miami Leukemia Symposium

IDH Inhibitors in Myeloid Malignancies: What Are the Mechanisms of R…

Feat. E. Stein
06:19
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review of Frontline CLL: Is There a Role for FCR in 2020 an…

Feat. A. Mato
07:59
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review of Frontline CLL: Can We Improve CIT by Adding a Nov…

Feat. A. Mato
05:08
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Combinations or Sequences of Targeted Agents in C…

Feat. A. Mato
04:52
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Venetoclax in the R/R CLL: With Additional Follow…

Feat. A. Mato
08:21
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Overcoming BTKi Resistance in CLL: Era of Non-Cov…

Feat. A. Mato
15:19
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

29 y/o Male w/ CML: Allograft vs. 3rd Line Therapy - Transplant Is A…

Feat. M. Mauro
15:59
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

New Kinase Inhibitors for CML: Asciminib, PF-114, & HQP1351

Feat. M. Mauro
27:00
Indy Hematology Review

Acute Myeloid Leukemia - Overview of Available Novel Agents with Uni…

Feat. M. Tallman
07:46
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Oral Abstract CML-044: Treatment-Free Remission (TFR) in Patients wi…

Feat. M. Mauro
17:58
Memorial Sloan Kettering Cancer Center

Front-line Strategies in Ph-negative ALL

Feat. M. Geyer
13:41
Memorial Sloan Kettering Cancer Center

Updates and Challenges in the Management of Chronic Myeloid Leukemia…

Feat. M. Mauro
17:13
Memorial Sloan Kettering Cancer Center

Multi-drug Resistant and Intolerant CML: What to Do?

Feat. M. Mauro
08:42
Memorial Sloan Kettering Cancer Center

IDH Inhibitors in AML

Feat. E. Stein